Related Experiment Video
Updated: Jun 1, 2026
Predictive Immune Modeling of Solid Tumors
Published on: February 25, 2020
Questions from the fourth son: a clinician reflects on immunomonitoring, surrogate markers and systems biology
1Wiseman Research Initiatives, LLC, Pasadena, CA 91106, United States. clwmd@aol.com
Abstract:
The fourth son is the one who doesn't even know how to ask a question. Tumor immunology is challenged by the failure to identify reliable surrogate markers in vaccine and other experimental therapies for cancer; perhaps investigators haven't yet asked the right questions. Unlike prophylactic vaccines for infectious disease, where the development of antibody is considered a satisfactory endpoint, no such endpoint exists for human therapeutic vaccines. Why is this? Despite an extensive roster of in vitro assays that correlate immune responses to favorable clinical outcomes, no assay is sufficiently reliable to be usefully predictive for vaccine therapy. The discussion reviews some of the historical developments in tumor immunology and the problem of defining a causal relationship when strong correlations are identified. The development of mathematical models from empirical data may help inform the clinician/scientist about underlying mechanisms and help frame new testable hypotheses.
Insights
Identifying reliable markers for cancer vaccines remains difficult because the right questions haven't been asked. Developing predictive assays for therapeutic cancer vaccines is crucial for advancing treatment strategies.
Area of Science:
- Oncology
- Immunology
- Biostatistics
Background:
- Cancer vaccine development faces challenges in identifying reliable surrogate markers for efficacy.
- Unlike infectious disease vaccines, human therapeutic cancer vaccines lack a universally accepted endpoint for success.
Purpose of the Study:
- To review historical challenges in tumor immunology and marker identification for cancer vaccines.
- To explore the difficulties in establishing causal relationships between immune responses and clinical outcomes.
- To propose the use of mathematical modeling to aid in understanding mechanisms and formulating hypotheses.
Main Methods:
- Literature review of tumor immunology and vaccine therapy.
- Analysis of the limitations of current in vitro assays for predicting therapeutic vaccine efficacy.
- Discussion of the potential of mathematical modeling for hypothesis generation.
Main Results:
- Current in vitro assays show poor reliability in predicting clinical outcomes for cancer vaccine therapy.
- Historical approaches have struggled to define clear surrogate markers for therapeutic cancer vaccines.
- Mathematical modeling offers a potential avenue to elucidate mechanisms and guide future research.
Conclusions:
- The lack of reliable surrogate markers hinders the advancement of cancer vaccine therapy.
- Rethinking the questions asked in tumor immunology research is essential.
- Mathematical modeling of empirical data may provide new insights and testable hypotheses for cancer vaccine development.
